literature

HIV mutation literature information.

Clinically relevant genotype interpretation of resistance to didanosine.

PMID: 15855490 2005 Antimicrobial agents and chemotherapy

Abstract: Eight mutations were associated with a reduced response to ddI, M41L, D67N, T69D, L74V, V118I, L210W, T215Y/F, and K219Q/E, and two mutations were associated with a better response, K70R and M184V/I.

Abstract: The best prediction of the virologic response to ddI was obtained with a composite score comprising mutations added and subtracted (set II, M41L + T69D + L74V+ T215Y/F + K219Q/E - K70R -

Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR.

PMID: 15893572 2005 Journal of virological methods

Abstract: This sensitive and reliable point-mutation assay, analyzing M184I/V and other important mutations, will be fruitful in gaining new scientific knowledge about the kinetics of resistance mutations in minor viral populations of HIV-1 infected patients at failure of antiretroviral therapy.

High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.

PMID: 16014919 2005 Journal of virology

Abstract: K65R and M184V/I seemed to arise in separate clones, followed by an enrichment of viruses containing both mutations.

Abstract: M184V/I was selected more frequently than K65R at W4.

Abstract: All three nucleoside analogs are known to select the K65R and/or M184V/I mutation.

Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.

PMID: 16038473 2005 Antiviral therapy

Abstract: RESULTS: Eight mutations were associated with a reduced virological response to ddI: M41L, D67N, T69D, L74V, V1181, L210W, T215Y/F and K219Q/E and two mutations with a better virological response: K70R and M184V/I.

In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.

PMID: 16127074 2005 Antimicrobial agents and chemotherapy

Abstract: Serial passage of human immunodeficiency virus type 1 in MT-2 cells in increasing concentrations of the d- and l-enantiomers of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) resulted in the selection of viral variants with reverse transcriptase substitutions M184I or M184V for l-d4FC and I63L, K65R, K70N, K70E, or R172K for d-d4FC.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

PMID: 16152754 2005 Antiviral therapy

Abstract: Eight out of nine patients with available genotype after virological failure showed resistance mutations to NVP (Y181C and others) and 3TC (M184V/I), and four of them also had ddI resistance (L74V).

Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.

PMID: 16452063 2005 HIV clinical trials

Abstract: 14 pts with K65R and M184V/I were given a rescue therapy with a successful outcome (< 50 copies/mL; median follow-up 48 weeks).

Abstract: 76% of pts developed K65R and M184V/I mutations by W24, and 19% developed M184V/I alone.

Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.

PMID: 19825125 2005 Journal of the International AIDS Society

Discussion: However, M184I is rare in clinical samples and the switch from isoleucine to valine results from a A G transition.

Discussion: The G A hypermutation is the cause of the M184I substitution which commonly occurs prior to M184V.

Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.

PMID: 15280484 2004 Journal of virology

Abstract: Several mutations associated with resistance to antiviral nucleoside analogs (K65R, L74V, E89G, Q151N, and M184I) dramatically increased RT template-switching frequencies by two- to sixfold in a single replication cycle.

High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.

PMID: 15280780 2004 AIDS (London, England)

Abstract: CONCLUSION: These analyses should assist in the creation of rules for genotypic drug resistance algorithms for a better reflection of the impact of individual TAM and also the impact of M184I/V on resistance.

Abstract: DESIGN: An HIV genotypic/phenotypic database with over 27 000 samples was used to obtain the median fold change (5-95th percentile) in NRTI phenotypic susceptibility for viruses from patients containing individual TAM with or without the M184I or V mutation and for wild-type patient viruses.

Abstract: In the presence of the M184I/V mutation, re-sensitization to some drugs, including zidovudine, stavudine and tenofovir was observed despite the presence of a TAM.

Browser Board

Co-occurred Entities

Filtrator